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The Quality and Outcomes of Care 
Provided to Patients with Cirrhosis by 
Advanced Practice Providers
Elliot B. Tapper ,1,2 Shengchen Hao,3 Menghan Lin,3 John N. Mafi,4,5 Heather McCurdy,2 Neehar D. Parikh ,1,2  
and Anna S. Lok1,2
Cirrhosis is morbid and increasingly prevalent, yet the U.S. health care system lacks enough physicians and special-
ists to adequately manage patients with cirrhosis. Although advanced practice providers (APPs) can expand access to 
cirrhosis-related care, their impact on the quality of care remains unknown. We sought to determine the effect on 
care quality and outcomes for patients managed by APPs using a retrospective analysis of a nationally representative 
American commercial claims database (Optum), which included 389,257 unique adults with cirrhosis. We evalu-
ated a complication of process measures (i.e., rates of hepatocellular carcinoma [HCC] screening, endoscopic varices 
screening, and use of rifaximin after hospitalization for hepatic encephalopathy) and outcomes (30-day readmissions 
and survival). Compared with patients without APP care, patients with APP care had higher rates of HCC screen-
ing (adjusted odds ratio [OR] 1.23, 95% confidence interval 1.19, 1.27), varices screening (OR 1.20 [1.13, 1.27]), 
use of rifaximin after a discharge for hepatic encephalopathy (OR 2.09 [1.80, 2.43]), and reduced risk of 30-day re-
admission (OR 0.68 [0.66, 0.70]). Gastroenterology/hepatology consultation was also associated with improved qual-
ity metric performance compared with primary care; however, shared visits between gastroenterologists/hepatologists 
and APPs were associated with the best performance and lower 30-day readmissions compared with subspecialty 
consultation without an APP (OR 0.91 [0.87, 0.95]. Multivariate analysis adjusting for comorbidities, liver disease 
severity, and other factors including gastroenterology/hepatology consultation showed that patients seen by APPs 
were more likely to receive consistent HCC and varices screening over time, less likely to experience 30-day read-
missions, and had lower mortality (adjusted hazard ratio 0.57, 95% confidence interval 0.55, 0.60). Conclusion: APPs, 
particularly when working with gastroenterologists/hepatologists, are associated with improved quality of care and 
outcomes for patients with cirrhosis. (Hepatology 2020;71:225-234).
SEE EDITORIAL ON PAGE 11
Cirrhosis is common, affecting up to 5  million Americans, and its prevalence is increasing.(1-4) It is characterized by poor quality of life and 
life-limiting complications such as variceal hemorrhage, 
ascites, hepatic encephalopathy (HE), and hepatocellular 
carcinoma (HCC).(5-7) There are standard measures that 
can be undertaken to forestall many of these complica-
tions and improve patient outcomes. In 2010, Kanwal 
et al. translated many key standards for the care of patients 
with liver disease into measurable quality indicators.(8) 
These indicators include imaging-based screening for 
HCC,(9) endoscopic screening for varices,(10) immuni-
zation against viral hepatitis, and optimal therapy for 
HE.(11) Both the American Association for the Study of 
Liver Diseases and advanced liver disease workgroups in 
the Department of Veterans Affairs (VA) have adopted 
these measures into practice guidelines. Unfortunately, 
substantial gaps in implementation persist.(12)
Abbreviations: APP, advanced practice provider; CI, confidence interval; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HR, 
hazard ratio; IQR, interquartile range; MD, medical doctor; OR, odds ratio; VA, Veterans Affairs.
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A major barrier to optimal care for cirrhosis is lim-
ited access to subspecialty care. Most patients with 
cirrhosis are not co-managed by a gastroenterology- 
trained or hepatology-trained specialist.(13,14) Previous 
studies have demonstrated that advanced practice pro-
viders (APPs) provide care that is equivalent in qual-
ity to medical doctors (MDs) in both primary care 
and specialty care when their practice is focused on 
one condition.(15-18) However, data are lacking regard-
ing quality metric performance for APPs in patients 
with cirrhosis. Herein, we examine a large commer-
cial claims database to assess the quality of APP care 
and the impact on outcomes in patients with cirrhosis 
with or without subspecialty consultation.
Materials and Methods
We analyzed the 2001-2015 Optum Clinformatics 
DataMart (Eden Prairie, MN), which includes nation-
ally representative information for 77,883,541 unique 
patients covered with private insurance, including 
Medicare Advantage. Enrollees are followed longitu-
dinally across inpatient and outpatient settings. Data 
for the present study were limited to adults with at 
least two cirrhosis claims. All coding definitions are 
provided in Supporting Table S1.(19-21) This study was 
exempted from review by the University of Michigan 
Institutional Review Board.
QUalIty INDICatoRS  
aND oUtCoMeS
We chose four quality indicators that were easily 
abstracted from administrative data: screening for 
HCC, screening for varices, and prescription of rifax-
imin following a hospitalization for HE. We then 
examined two clinical outcomes: 30-day readmissions 
and mortality. The sources and definitions of denomi-
nators and numerators for quality metrics are detailed 
in Supporting Table S2. Finally, we examined health 
care expenditures by combining the charges associated 
with all procedures and visits (CPT and HCPCS 
codes) incurred by each patient per person-year. 
We excluded non-liver surgical procedures, non-liver 
oncologic therapies, and cardiac or electrophysiolog-
ical procedures.
eXpoSUReS
Provider type was our principal exposure variable. 
Specifically, we evaluated the impact of APP vis-
its (nurse practitioners or physician’s assistants). We 
included APP visits that occurred in either primary 
care or gastroenterology/hepatology clinics, some of 
which occurred as “shared visits” with gastroenterology/ 
hepatology specialists on the same day of service. We 
collected additional exposure variables for complete 
description of the cohort and risk adjustment. These 
included age, sex, race, education, Charlson comorbid-
ity index (modified to exclude liver disease),(22) etiol-
ogy of liver disease, complications of cirrhosis, number 
of outpatient visits, and evaluation by a provider asso-
ciated with a transplant facility. Liver disease severity 
was captured using a combination of diagnosis and 
procedure codes (cirrhosis complications such as HE 
and procedures such as paracentesis and portosystemic 
shunt placement). Transplant facility was defined as 
any center that performed a liver transplant within the 
same year of service.
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StatIStICal aNalySeS
To analyze outcomes, we used four strategies. 
First, we performed logistic regression analyses to 
determine the relative impact of APP evaluation 
on practice metrics, limiting the cohort for evalu-
ation to those with at least 12  months’ follow-up 
(Fig. 1). To account for the effect of gastroenterol-
ogy/hepatology consultation, we evaluated multiple 
scenarios:
1. Scenario 1: Patients with any APP visit versus no 
APP visits. (Analyses were adjusted for gastroen-
terology/hepatology consultation if it occurred.)
FIg. 1. Association of provider type with process measures and 30-day readmissions. Adjusted ORs for multiple metrics are presented 
to show the quality of care provided by various health care providers. Raw data including unadjusted estimates are presented in 
Supporting Table S3A-D. (A) Compared with patients who were never seen by an APP, those who were seen by an APP, regardless 
of presence or absence of gastroenterologist/hepatologist consultation, were marginally more likely to receive screening for HCC and 
varices, more likely to receive rifaximin after discharge for HE, and less likely to experience a 30-day readmission. (B) Patients seen 
by APPs without gastroenterologists/hepatologists were less likely to receive care that satisfies the practice metrics, but also less likely 
to experience a 30-day readmission compared with patients seen by gastroenterologists/hepatologists without APPs. (C) Patients seen 
by gastroenterologists/hepatologists with assistance from APPs received better care and had less readmissions compared with those 
seen by gastroenterologists/hepatologists alone, except for varices screening, in which there was no difference. (D) Patients seen by 
gastroenterologists/hepatologists alone received better care for all measures and had less readmissions compared with those not seen by 
gastroenterologists/hepatologists or APPs.
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2. Scenario 2: Patients with neither APP nor 
gastroenterology/hepatology consultation versus 
gastroenterology/hepatology consultation without 
any APP visits.
3. Scenario 3: Patients with APP and gastroenterology/ 
hepatology consultation versus gastroenterology/
hepatology consultation but no APP.
4. Scenario 4: Patients with gastroenterology/hepatology 
consultation but no APP versus neither APP nor 
gastroenterology/hepatology consultation.
Second, we analyzed two “pre/post” cohorts to 
assess the impact of APP involvement (Table 2). 
In the first cohort, we included all patients with 
6  months of coverage before and after a first visit 
with an APP. For the outcome of endoscopic 
screening, we excluded patients who had an endos-
copy examination prior to the 1-year period ana-
lyzed, given the recommended interval for screening 
(Supporting Table S2). For this cohort, we adjusted 
for the impact of gastroenterology/hepatology con-
sultation as a time-varying covariate in the event 
that a patient received such a consultation. In the 
second pre/post cohort, we included all patients 
with 6 months of coverage before and after a shared 
visit with a gastroenterologist/hepatologist MD and 
an APP (their first visit with either provider type in 
the database).
Third, we determined the incidence rate (per person- 
year) of each practice metric. Practice metric events 
were compared between groups of patients with and 
without APP involvement using incidence rate ratios 
derived from negative binomial regressions (Table 3).
Fourth, we used a time-dependent Cox propor-
tional hazards model to determine the impact of APP 
evaluation on survival using time-varying covariates 
to adjust the hazard ratio (HR) (Table 4). Patients 
were censored if they received a liver transplant 
or were lost to follow-up due to loss of insurance 
coverage. The reasons for loss of coverage are not 
known but generally include changes in employment 
(and thus insurer) or transition to a public insurer 
(Medicare/Medicaid). This data set is linked to the 
social security death index and thus mortality data 
was complete in the data set’s “death view.” For those 
who died within 3  months after loss of coverage, 
death rather than loss of coverage was considered 
the outcome. Gastroenterologists and hepatologists 
were considered separately, as hepatology consulta-
tion may reflect management at a transplant facility. 
To adjust as fully as possible for severity of illness, 
we added covariates for common infections that 
are linked with adverse outcomes in patients with 
cirrhosis (Supporting Table S1).(23) We addressed 
biases in multiple ways. First, we used Fine-Gray 
modeling to account for the competing risk of liver 
transplantation.(24) Second, we addressed the risk 
of residual immortal time bias—despite the use of 
time-dependent Cox modeling—using a Landmark 
analysis,(25) setting the cohort entry as those seen 
by an APP or not at the time of cirrhosis diagnosis. 
Third, to further address confounding by indication, 
we performed a 1:1 propensity score matching for 
exposure to APP care.
Descriptive statistics are presented as the median 
and interquartile range (IQR) for continuous vari-
ables and as the number and percent for categorical 
variables. Comparisons of continuous variables were 
performed using the Student t test and the Wilcoxon 
rank sum test for parametric and nonparametric vari-
ables, respectively. Categorical variables were compared 
using a chi-squared test. All analyses were performed 
using R (packages dplyr, plyr, stringr, comorbidity, 




Descriptive statistics for our population are given 
in Table 1. Of the 389,257 patients included, 57% 
never had a visit with an APP. Although the differ-
ences in characteristics of the cohorts with and with-
out APP visits were statistically significant in many 
aspects, they were small and not clinically meaningful 
except for medical comorbidities that were more com-
mon in the cohort with APP visits than those with-
out (70% versus 53% with at least three comorbidities 
[P < 0.001]).
Overall, patients were followed for a median of 
5.00 (IQR 2.33-9.00) person-years, and 5.92 (3.00-
9.58) and 4.41 (2.00-8.33) for those with more than 1 
and 0 APP visits, respectively. The median number of 
outpatient visits per person-year for patients seen by 
APP and those who were not was 8.8 (4.8-14.4) and 
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4.7 (2.3-8.5), respectively. The most common endpoint 
was censoring (303,139 [77.8%]; 134,936 censored 
patients were alive at the study end date), occurring 
within 5.25 (2.50-9.33) person-years. Overall, 83,647 
(21.5%) died within 4.17 (1.91-7.58) person-years, 
and 2,471 (0.63%) received a liver transplant within 
2.64 (1.11-5.34) person-years. We counted death and 
not loss of coverage as an outcome in 6,872 patients 
who lost coverage within 3 months prior to mortality; 
9,366 patients died within 6 months and 13,874 died 
within 1 year of loss of coverage.
aSSoCIatIoN oF app 
INVolVeMeNt WItH pRaCtICe 
MetRICS IN tHe CoNteXt 
oF gaStRoeNteRology/
Hepatology CoNSUltatIoN
The quality of care provided by APP in the pres-
ence and absence of gastroenterology/hepatology con-
sultation is depicted in Fig. 1. In scenario 1 (Fig. 1A), 
we show that, compared with patients never seen by 
an APP, management by an APP with or without 
gastroenterologists/hepatologists was not different 
regarding rates of screening for HCC, but APP man-
agement was associated with a slightly higher rate of 
varices screening and much higher rates of rifaximin 
use after discharge for HE (OR 1.31 [1.20, 1.44]) and 
lower 30-day readmissions (OR 0.68 [0.66, 0.70]). 
When we compared APP management without 
gastroenterology/hepatology consultants to manage-
ment by gastroenterologists/hepatologists without 
assistance by APPs (scenario 2, Fig. 1B), APP manage-
ment alone was inferior for all measures except 30-day 
readmissions (OR 0.61 [0.58, 0.63]). In Fig. 1C (scenario 
3), we show that management by gastroenterologists/
hepatologists with APPs was superior to management 
by gastroenterologists/hepatologists without APPs in 
all practice metrics as well as 30-day readmissions (save 
for endoscopic screening). Finally, Fig. 1D (scenario 
4) shows that patients seen by gastroenterologists/ 
hepatologists without APPs received much higher 
quality management in all practice metrics, but also 
slightly higher 30-day readmissions than patients seen 
by neither gastroenterologists/hepatologists nor APPs.
pRaCtICe MetRICS BeFoRe aND 
aFteR eValUatIoN By appS: 
NatURal eXpeRIMeNtS
In Table 2, we demonstrate the temporal associa-
tion with practice metric completion in two pre/post 
analyses of patients evaluated by an APP with or 
without gastroenterology/hepatology consultation. 
In the first analysis, APP evaluation was associated 
with improved HCC screening (adjusted odds ratio 
[OR] 1.23 [1.19, 1.27]), varices screening (OR 1.20 
[1.13, 1.27]), and use of rifaximin after a discharge for 
HE (OR 2.09 [1.80, 2.43]). In the second analysis, 
a similar and stronger relationship was observed for 
patients whose first APP visit was a shared visit with a 






Age (median IQR) 60 (48-70) 58 (46-69) <0.001




African American 10.30% 9.73%
Hispanic 9.47% 12.14%




<12th grade 0.83% 1.34%
High school 32.62% 31.38%
Less than bachelor’s 
degree
50.94% 46.49%










Alcoholic cirrhosis 33.94% 30.98% <0.001




HE 18.31% 16.33% <0.001
Ascites 31.19% 41.71% <0.001
Varices 13.19% 14.00% <0.001
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gastroenterologist/hepatologist. Notably, the baseline 
rate of metric completion was higher for patients in 
the second analysis.
aSSoCIatIoN BetWeeN app 
INVolVeMeNt aND QUalIty 
CaRe aND oUtCoMeS oVeR 
tIMe
To evaluate the consistency of effect as well as 
adjust for the time each patient is under evaluation, 
we analyzed the impact of APP visits on the aver-
age rate of quality metrics over time (Table 3). For 
all metrics, APP involvement was associated with 
improved delivery of care: increased HCC screen-
ing (adjusted incidence rate ratio 1.61 [1.60, 1.63]), 
increased varices screening (1.51 [1.49, 1.54]), and 
decreased 30-day readmissions (0.88 [0.87, 0.90]).
aSSoCIatIoN BetWeeN app 
CaRe aND MoRtalIty
Table 4 details the associations between clinical 
and demographic features and mortality. As expected, 
older age, patients with more medical comorbidities, 
and those with more advanced cirrhosis had higher 
taBle 2. pre/post “experiments”: Relative practice Metric performance after an app Visit that Was (or Was Not) Shared 
With a gastroenterologist/Hepatologist
Screening for HCC Endoscopy Screening for Varices On Rifaximin After Discharge for HE
Before and after an APP visit
Denominator 97,013 84,138 5,082
Metric satisfied prior to APP visit 26.1% 7.2% 7.9%
Metric satisfied after APP visit 30.1% 8.9% 14.8%
OR (95% CI) 1.27 (1.19, 1.24) 1.19 (1.15, 1.24) 2.02 (1.78, 2.30)
Adjusted OR (95% CI) 1.23 (1.19, 1.27) 1.20 (1.13, 1.27) 2.09 (1.80, 2.43)
Before and after visit with both GI/hep and APP
Denominator 4,830 3,593 572
Metric satisfied prior to GI/hep and APP visit 44.8% 12.4% 9.3%
Metric satisfied after GI/hep and APP visit 55.6% 27.2% 27.4%
OR (95% CI) 1.54 (1.42, 1.67) 2.66 (2.35, 3.01) 3.70 (2.64, 5.19)
Adjusted OR (95% CI) 1.58 (1.45, 1.73) 2.84 (2.48, 3.24) 4.08 (2.34, 7.13)
Note: Patients in both cohorts were seen by primary care MDs prior to APP involvement; in the former they could have seen a gas-
troenterologist/hepatologist, but in the latter, a gastroenterology/hepatology consultation first occurred in a shared visit with an APP. 
Patients were censored from the evaluation of HCC screening at the time of an HCC diagnosis. Patients were excluded from the 
denominator for endoscopic screening if they experienced variceal bleeding at any point or if they had an endoscopy within 1 year 
prior to the period evaluated. All adjustments included age, sex, race, education, Charlson comorbidity index, etiology of liver disease, 
complications of cirrhosis, number of outpatient visits, and evaluation by gastroenterologists or hepatologists.
Abbreviations: GI, gastroenterologist; hep, hepatologist.
taBle 3. Cumulative adherence to practice Metrics associated With Visits to app
Screening for HCC (Screens 
per Person-Year)
Screening for Varices 
(Endoscopy per Person-Year)
30-Day Readmissions per 
Discharge
Number of events in patients seen by APP per 
person-year, median (IQR)
0.75 (0.40-1.46) 0.35 (0.21-0.59) 0 (0-0.46)
Number of events in patients never seen by 
APP per person-year, median (IQR)
0.45 (0.22-0.89) 0.24 (0.13-0.44) 0 (0.0-0.5)
Incidence rate ratio (95% CI) 1.73 (1.72, 1.74) 1.48 (1.47, 1.49) 0.90 (0.89, 0.91)
Adjusted incidence rate ratio (95% CI) 1.61 (1.60, 1.63) 1.51 (1.49, 1.54) 0.88 (0.87, 0.90)
Note: The incidence rate ratios present a measure of the relative rate of events between patients managed (at least in part) by APPs, 
accounting for the time under evaluation. The adjusted measures account for demographics, clinical factors (Table 1), consultation by 
gastroenterologists/hepatologists, number of outpatient visits, and interaction terms for APP and gastroenterology/hepatology. Patients 
were censored from all analyses at the time of death or loss of coverage. Patients were censored from HCC screening metrics at the time 
of HCC diagnosis and from screening varices metrics at the time of variceal hemorrhage.
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HRs for mortality. APP involvement was associated 
with reduced risk of death (adjusted HR 0.57, 95% 
confidence interval [CI] 0.55, 0.60). When analyses 
account for the competing risks of death and trans-
plant, the adjusted HRs for death and transplant 
associated with APP involvement were 0.57 (95% CI 
0.55, 0.60) and 0.33 (95% CI 0.21, 0.50), respectively 
(Supporting Table S3). We performed a landmark 
analysis to further reduce the risk of immortal time 
bias (Supporting Table S4). In this case, the adjusted 
HR for death associated with APP management was 
0.80 (95% CI 0.75, 0.85). In Supporting Table S5 we 
provide the results of a propensity-score matching 
procedure and show that APP care remains inversely 
associated with mortality (HR 0.43, 95% CI 0.41, 
0.45).
aSSoCIatIoN BetWeeN 
app aND HealtH CaRe 
eXpeNDItUReS
We evaluated the association between APP involve-
ment and charges incurred per person-year (Supporting 
Table S6). APPs were associated with increased charges 
overall, $9,619 (IQR 5,041-18,183) compared with 
$4,450 (IQR 2,143-9,033) for patients who were not 
co-managed by APP. When the analysis was restricted 
to outpatient charges alone, the difference was a median 
of $6,196 per person-year compared with $2,756 
for non-APP. Adjusting for confounders including 
gastroenterology/hepatology involvement and disease 
severity, APPs were associated with increased charges, 
incidence rate ratio 1.79 (95% CI 1.77-1.80). Overall, 
these charges reflect 8,858 unique procedure and visit 
codes. The top 20 sources of health care expenditure 
by weight (charges multiplied by frequency) included 
procedure codes related to transthoracic echocardiog-
raphy, magnetic resonance and computed tomography, 
liver biopsy, laparoscopic liver resection, endoscopy, 
colonoscopy, and emergency department and outpa-
tient visits.
Discussion
The prevalence of cirrhosis in the United States is 
increasing, outstripping the capacity of specialists to pro-
vide optimal care. This study of a large commercial claims 
database covering more than 380,000 patients with cir-
rhosis demonstrates that care from an APP was asso-
ciated with improved quality metric adherence, reduced 
readmissions, and potentially decreased mortality.
appS IMpRoVe tHe QUalIty oF 
CaRe pRoVIDeD to patIeNtS 
WItH CIRRHoSIS
Quality Metrics
We chose to examine screening for HCC, because 
it can be ordered by any provider and is associated 






Age (per year) 1.05 (1.05, 1.05) 1.04 (1.04, 1.04)
Female sex 0.76 (0.75, 0.77) 0.91 (0.89, 0.93)
Asian race 0.79 (0.75, 0.83) 0.75 (0.71, 0.79)
African American race 1.10 (1.07, 1.13) 1.07 (1.04, 1.09)
Hispanic 0.80 (0.78, 0.82) 0.67 (0.65, 0.69)
Charlson comorbidity index  
(per point)
1.20 (1.19, 1.20) 1.10 (1.09, 1.11)
Alcoholic cirrhosis 1.32 (1.30, 1.34) 1.09 (1.05, 1.12)
Hepatitis C 0.83 (0.81, 0.85) 0.98 (0.95, 1.01)
Nonalcoholic, nonviral cirrhosis 0.90 (0.88, 0.92) 1.01 (0.97, 1.02)
Ascites 2.30 (2.26, 2.34) 1.80 (1.76, 1.84)
Paracentesis 2.42 (2.37, 2.47) 1.75 (1.70, 1.79]
Spontaneous bacterial peritonitis 2.30 (2.20, 2.40) 1.07 (1.02, 1.13)
Varices 1.12 (1.10, 1.15) 1.00 (0.97, 1.02)
Transjugular intrahepatic  
portosystemic shunt
1.75 (1.63, 1.87) 1.01 (0.93, 1.10)
HE 2.05 (2.02, 2.09) 1.54 (1.51, 1.58)
HCC 2.33 (2.27, 2.40) 1.78 (1.72, 1.84)
Dialysis 1.69 (1.64, 1.75) 1.09 (1.05, 1.13)
APP visit 0.70 (0.69, 0.71) 0.57 (0.55, 0.60)
Gastroenterology visit 
(non-hepatology)
0.99 (0.97, 1.00) 1.39 (1.36, 1.43)
Hepatology visit 0.78 (0.75, 0.80) 0.93 (0.89, 0.98)
Transplant facility 0.84 (0.83, 0.86) 0.83 (0.81, 0.84)
Note: Patients were censored for transplant or loss of coverage 
more than 3  months prior to date of death. For adjusted mod-
els we also included adjustment for number of outpatient visits, 
shared visits between MDs and APPs, as well as interaction terms 
for APP and gastroenterology as well as APP and hepatology. 
The variable for APP visits included any APP visit (alone or in 
conjunction with an MD). To adjust further for illness severity, 
we included diagnosis codes for sepsis, bacteremia, urinary tract 
infection, pneumonia, clostridium difficile infection, cellulitis, 
and cholangitis.
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with the receipt of curative therapy and improved 
overall survival,(26) yet fewer than 1 in 5 patients 
with cirrhosis receives an HCC screening.(12) 
Efforts to improve HCC screening rates, including 
reminders in the electronic health record, mailed 
invitations, and staff dedicated to facilitating screen 
completion, have had modest effects.(12,27) We now 
report strong improvements in the rate of HCC 
screening associated with APP management (inci-
dence rate ratio 1.61, 95% CI 1.60, 1.63). In con-
trast, likely because endoscopy has to be scheduled 
by gastroenterologists’ offices, we found only modest 
improvements in endoscopic screening for varices 
after APP management (with or without gastroen-
terology consultation).
Rifaximin is recommended for secondary prophy-
laxis of HE. We observed a marked rate of improve-
ment in rifaximin use after discharge for HE following 
an APP visit. Rifaximin use often requires an exten-
sive prior-approval process. APPs may have a more 
important role in tasks that require additional efforts 
outside of the traditional clinical workflow.
outcomes
One in every 4 patients with admissions for cirrho-
sis will be readmitted within 30 days.(12) Their individ-
ual risk is commensurate with disease severity, burden 
of comorbidities, and strength of social support. Few 
interventions aside from the use of rifaximin for HE 
have been linked with reduced readmissions.(12,28) 
In our study, we observed a reduced rate of 30-day 
readmissions in patients managed by APPs. Given 
the morbidity and costs of repeated hospitalizations 
among patients with cirrhosis, further research to 
explore the role of APPs in providing timely post- 
discharge clinic follow-up is warranted.
Finally, we found that care by an APP was asso-
ciated with a lower risk of death, adjusting for 
gastroenterology or hepatology involvement. The 
magnitude of benefit associated with APP care was 
substantial and robust across landmark and compet-
ing-risk analyses. Both outcome measures evaluated 
(30-day readmissions and mortality) favored APPs 
independent of gastroenterology/hepatology con-
sultation. Although the mechanism deserves further 
study, as informed by improved quality metric adher-
ence, care provided by APPs appears to be detail- 
oriented and effective.
apps and Health Care Charges
Consistent with our finding that APPs are associ-
ated with increased quality metric performance, which 
involves use of radiology tests and other procedures, 
we found that APPs were associated with a nearly 
2-fold increase in health care expenditures. This 
translates to an incremental $5,169 in charges per 
person-year. The main procedures that drove charges 
were radiology tests, endoscopic procedures, and liver 
resection. Prospective costing analyses are needed to 
confirm these associations as well as the appropriate-
ness of the ordered tests/procedures. In conjunction 
with the associated improvement in survival, these 
increased charges could be cost-effective.
appS aRe aN INtegRal 
CoMpoNeNt oF a MoDel FoR 
optIMal CaRe
APPs are viewed as a key component of primary 
care delivery, in which substantial data suggests that 
APPs provide care equivalent in quality to MDs.(15-18) 
A randomized controlled trial comparing nurse prac-
titioners practicing independently versus physicians 
in primary care showed no differences in mortality or 
other important health outcomes.(29) APP visits are 
associated with lower hemoglobin A1C levels and sys-
tolic blood pressure, as well as longer duration of visits 
and frequently lower costs.(15,30) Further, APPs are not 
more likely to provide low-value care, such as magnetic 
resonance imaging for headache.(16) Beyond primary 
care, when APPs are experienced and the scope of prac-
tice is well-defined, such as care of patients infected 
with human immunodeficiency virus, the quality of 
care provided is no different than that of MDs.(17)
In this study, we extend the research on quality of 
APP care by examining its impact on patients with 
cirrhosis. Cirrhosis is a highly complex medical con-
dition with multiple challenging needs, ranging from 
unique indications for screening tests to frequent 
needs for lab monitoring and adjustment of medica-
tions such as diuretics and life-threatening complica-
tions like variceal bleeding. Roughly half of our study 
cohort had decompensated cirrhosis. Even in the con-
text of these highly specialized needs, our data show 
that patients with cirrhosis received higher quality 
care when seen by APPs. We showed that compared 
with patients never seen by an APP, APP visits were 
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associated with sustained increases in quality metric 
adherence over time as well as reduced 30-day read-
mission risk, even when adjusted for co-management 
by gastroenterologists/hepatologists.
Overall, our data suggest that the optimal care for 
patients with cirrhosis may require both gastroenterolo-
gists/hepatologists and APPs. Although APP involve-
ment was associated with higher quality care compared 
with no APP, the quality of care provided by APPs 
without gastroenterologists/hepatologists was inferior to 
that provided by gastroenterologists/hepatologists alone 
in all categories except 30-day readmissions. Our find-
ings confirm a prior study from the VA, in which gas-
troenterology/hepatology consultation was associated 
with improved outcomes in patients with cirrhosis.(14) 
However, access to gastroenterologists/hepatologists is 
limited; among Medicare and VA enrollees, 55% and 
67% of patients with cirrhosis, respectively, are never 
evaluated by a gastroenterologist/hepatologist.(13,14) The 
key opportunity suggested by our data is to encourage 
care delivery that leverages broader availability of APPs, 
to implement a care plan that is co-developed with 
gastroenterologists/ hepatologists.
CoNteXtUal FaCtoRS
Our data must be interpreted in the context of the 
study design. First, we adjusted for confounding fac-
tors as thoroughly as possible given these administra-
tive data, including diagnostic codes and procedures 
for cirrhosis complications; however, without access to 
laboratory values, we cannot directly adjust for indices 
of liver disease severity such as Child-Pugh-Turcotte 
classification and Model for End-Stage Liver Disease 
score. Although our study period predates recommen-
dations to consider foregoing endoscopic screening 
in patients with low liver stiffness and robust plate-
let counts, our data lack the factors needed to deter-
mine which patients could be safely excluded from 
the screening denominator. Second, as this is a study 
of a commercial insurance database, our findings may 
not generalize to patients with other insurance such 
as Medicaid, and are limited by the loss of follow-up 
when patients lost coverage after loss of employment or 
transition to public insurers. Third, we cannot know the 
reasons for test ordering. As indicated in Table 2, the 
preconsultation rate of metric completion was higher 
for patients who were referred to gastroenterologists/
hepatologists compared with those about to see an 
APP. It is possible that, in many cases, the “screening 
test” may have prompted the consultation (such as by 
disclosing ascites or varices). As the number of visits 
performed increases the likelihood that a provider sat-
isfies any given practice metric simply due to oppor-
tunity, we adjusted for the number of visits attended 
and provided pre/post cohorts to evaluate the tem-
poral effect of the first visit with a gastroenterologist/ 
hepatologist and/or APP. Fourth, we evaluated health 
care charges to the system, which are typically inflated 
over true costs. Furthermore, the charges we describe 
reflect the sum of all tests/procedures incurred for any 
given patient, to reflect the overall expenditures asso-
ciated with APP care. Prospective studies are needed 
to determine the charges/costs attributed to specific 
providers. Finally, APPs may not be a part of the 
health care apparatus in some countries; even within 
the United States there are variations in their scope of 
practice. In general, APPs often provide independent 
full-service health care, but some regions/states specify 
whether visits must be shared with MDs or whether 
prescriptions must be co-signed. Although we carefully 
evaluated the relative impact of shared (MD/APP) and 
independent (APP alone) visits, future research could 
assess the impact of regional differences in policy as 
well as temporal (before and after rules to liberalize 
APP practice) differences.
In conclusion, APPs, particularly when working in 
conjunction with gastroenterology/hepatology consul-
tation, are associated with improved quality of care and 
outcomes for patients with cirrhosis. These findings 
have important implications for the design of inter-
ventions to improve the quality of care among patients 
with cirrhosis. The modest incremental expenditures 
associated with APP care appear to be related to 
their association with improved quality metric perfor-
mance and, in the context of reduced mortality, may 
prove justifiable within the conventional definitions 
of cost-effectiveness. Efforts to provide APPs with 
training in specialty care, and to facilitate team man-
agement involving specialists and APPs to coordinate 
care for patients with cirrhosis, appear warranted.
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